share_log

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

Benzinga ·  Mar 26 14:34

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 338

Recommended

Write a comment